Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Suven Life Sciences will host an in-person interaction with institutional investors and analysts in Mumbai on July 17, 2026. The company confirmed no unpublished price-sensitive information will be shared during this meeting.
Jul 14 2026 12:06:07
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London. The presentations will include updates on its global Phase-3 Masupirdine clinical program and Usmarapride Phase-2 development.
Jul 10 2026 12:24:47
Suven Life Sciences Ltd - 530239 - Revised Outcome Of The Meeting Of Board Of Directors- Incorporation Of Wholly Owned Subsidiary (WOS) In Singapore
Suven Life Sciences Board approved the incorporation of a new wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore for bio-pharmaceutical R&D with an investment of up to $100 million. Additionally, the Board approved the allotment of 1.85 crore equity shares at Rs.134 per share, raising Rs.248.84 crore via warrant conversion.
Jul 08 2026 16:52:08
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Allotment
Suven Life Sciences' Board approved the allotment of 1.85 crore equity shares at Rs. 134 per share, raising Rs. 248.83 crore. These shares were issued to 17 non-promoter entities upon conversion of fully paid warrants.
Jul 08 2026 12:57:00
Suven Life Sciences Ltd - 530239 - Board Meeting Outcome for Outcome Of Board Meeting
Suven Life Sciences has incorporated a new wholly-owned subsidiary, Suven Neurosciences Pte. Ltd., in Singapore. The company will invest $100 million, focusing on clinical-stage biopharmaceutical development for neurological disorders.
Jul 08 2026 12:51:42
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences will participate in the BIO International Convention 2026 (June 22-25) in San Diego. The company will showcase its differentiated CNS clinical candidates and explore partnering strategies for its late-stage assets, including 62 pre-scheduled meetings.
Jun 22 2026 10:23:37
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences announced positive topline results from its Phase-2b clinical trial of Ropanicant for Major Depressive Disorder, demonstrating clinically meaningful improvement. A global Phase-3 registrational study for the drug is now being planned.
Jun 17 2026 12:34:57
Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences successfully completed its Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 PAM, demonstrating favorable safety and CNS activity. The drug will now advance to Phase-2 clinical development for Central Nervous System disorders. This marks a key pipeline milestone.
Jun 16 2026 09:25:54
Read More